IO Biotech, Inc. (IOBT)
NASDAQ: IOBT · Real-Time Price · USD
1.100
-0.010 (-0.90%)
Feb 21, 2025, 4:00 PM EST - Market closed
IO Biotech Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for IO Biotech stock have an average target of 9.33, with a low estimate of 6.00 and a high estimate of 12. The average target predicts an increase of 748.18% from the current stock price of 1.10.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 12, 2024.
Analyst Ratings
The average analyst rating for IO Biotech stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +990.91% | Nov 12, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +990.91% | Nov 6, 2024 |
Morgan Stanley | Morgan Stanley | Buy Maintains $4 → $6 | Buy | Maintains | $4 → $6 | +445.45% | Sep 16, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +990.91% | Sep 16, 2024 |
Piper Sandler | Piper Sandler | Buy Maintains $10 | Buy | Maintains | $10 | +809.09% | Sep 3, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.39
from -1.98
EPS Next Year
-1.36
from -1.39
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | n/a | n/a | 48.8M | |||
Avg | n/a | n/a | 18.2M | |||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | -1.37 | -1.08 | -0.85 | |||
Avg | -1.39 | -1.36 | -1.20 | |||
Low | -1.38 | -1.47 | -1.48 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | - | - | - | |||
Avg | - | - | - | |||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.